首页> 外文期刊>International journal of hematology >Identification of a homozygous JAK3 V674A mutation caused by acquired uniparental disomy in a relapsed early T-cell precursor ALL patient
【24h】

Identification of a homozygous JAK3 V674A mutation caused by acquired uniparental disomy in a relapsed early T-cell precursor ALL patient

机译:在复发的早期T细胞前体ALL患者中鉴定由获得性单亲二体性引起的纯合JAK3 V674A突变

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Investigation of genetic alterations associated with relapse in acute lymphoblastic leukemia (ALL) may help to identify druggable targets for specific therapies. Early T-cell precursor ALL (ETP-ALL) is a subtype of T-ALL with poor prognosis. Although the genetic landscape of ETP-ALL has been determined, genetic alterations related to the relapse of ETP-ALL have not been fully investigated. Here, we report the first patient with relapsed pediatric ETP-ALL to exhibit a homozygous JAK3 activating mutation, V674A, caused by acquired uniparental disomy (UPD). Single nucleotide polymorphism array analysis revealed acquired UPD (aUPD) at the 19p13.3-p12 locus only in leukemic cells at relapse. Sanger sequence of the JAK3 gene, which was located at 19p13.1 and frequently mutated in ETP-ALL, was performed in paired leukemic samples to determine homozygous JAK3 V674A mutation only in relapsed leukemic cells. In contrast, leukemic cells at initial diagnosis harbored hemizygous JAK3 V674A mutation. Further, whole-exome sequencing revealed mutations in 18 genes only in relapsed samples, although none of these was recurrent in T-ALL. These findings suggest that aUPD at 19p13.1 is partly associated with relapse in this patient. Pharmacological inhibition of JAK3 may be therapeutic in such cases.
机译:对与急性淋巴细胞白血病(ALL)复发相关的遗传改变的研究可能有助于确定特定疗法的药物靶标。早期T细胞前体ALL(ETP-ALL)是T-ALL的亚型,预后较差。尽管已经确定了ETP-ALL的遗传背景,但尚未全面研究与ETP-ALL复发有关的遗传改变。在这里,我们报告第一例复发性小儿ETP-ALL患者表现出由获得性单亲二体性(UPD)引起的纯合JAK3激活突变V674A。单核苷酸多态性阵列分析显示仅在复发时在白血病细胞中在19p13.3-p12位点获得了UPD(aUPD)。在配对的白血病样品中进行了位于19p13.1并经常在ETP-ALL中突变的JAK3基因的Sanger序列,以确定仅在复发的白血病细胞中的纯合JAK3 V674A突变。相反,最初诊断时的白血病细胞带有半合子JAK3 V674A突变。此外,全外显子组测序仅在复发的样本中揭示了18个基因的突变,尽管这些都没有在T-ALL中复发。这些发现表明,该患者19p13.1的aUPD部分与复发有关。在这种情况下,JAK3的药理抑制作用可能是治疗性的。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号